9. CONCLUSION

From the study findings it can be concluded that patient on capecitabine therapy with the DPD mutation was associated with severe toxicities. The therapeutic dose is justifiable with capecitabine treatment as there is no effect of the covariates influencing the capecitabine and its metabolite 5FU exposure.